The global endometrial cancer market is projected to grow from USD 31.09 billion in 2025 to USD 51.15 billion by 2034, expanding at a CAGR of 5.69%. Growth is fueled by increased awareness, rising adoption of minimally invasive surgical techniques, and a growing aging population across key regions.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Endometrial Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Endometrial Cancer Market, by Type of Cancer
8.1.1 Endometrial Carcinoma
8.1.1.1. Market Revenue and Forecast
8.1.2. Uterine Sarcomas
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Endometrial Cancer Market, by Type of Therapy
9.1.1. Immunotherapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Radiation Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Chemotherapy
9.1.3.1. Market Revenue and Forecast
9.1.4. Other of Therapies Synthetic Source
9.1.4.1. Market Revenue and Forecast
10.1. Endometrial Cancer Market, by Diagnosis Method
10.1.1. Biopsy
10.1.1.1. Market Revenue and Forecast
10.1.2. CT Scan Hysteroscopy
10.1.2.1. Market Revenue and Forecast
10.1.3. Pelvic Ultrasound
10.1.3.1. Market Revenue and Forecast
10.1.4. Other Diagnosis Methods
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type of Cancer
11.1.2. Market Revenue and Forecast, by Type of Therapy
11.1.3. Market Revenue and Forecast, by Diagnosis Method
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type of Cancer
11.1.4.2. Market Revenue and Forecast, by Type of Therapy
11.1.4.3. Market Revenue and Forecast, by Diagnosis Method
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type of Cancer
11.1.5.2. Market Revenue and Forecast, by Type of Therapy
11.1.5.3. Market Revenue and Forecast, by Diagnosis Method
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type of Cancer
11.2.2. Market Revenue and Forecast, by Type of Therapy
11.2.3. Market Revenue and Forecast, by Diagnosis Method
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type of Cancer
11.2.4.2. Market Revenue and Forecast, by Type of Therapy
11.2.4.3. Market Revenue and Forecast, by Diagnosis Method
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type of Cancer
11.2.5.2. Market Revenue and Forecast, by Type of Therapy
11.2.5.3. Market Revenue and Forecast, by Diagnosis Method
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type of Cancer
11.2.6.2. Market Revenue and Forecast, by Type of Therapy
11.2.6.3. Market Revenue and Forecast, by Diagnosis Method
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type of Cancer
11.2.7.2. Market Revenue and Forecast, by Type of Therapy
11.2.7.3. Market Revenue and Forecast, by Diagnosis Method
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type of Cancer
11.3.2. Market Revenue and Forecast, by Type of Therapy
11.3.3. Market Revenue and Forecast, by Diagnosis Method
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type of Cancer
11.3.4.2. Market Revenue and Forecast, by Type of Therapy
11.3.4.3. Market Revenue and Forecast, by Diagnosis Method
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type of Cancer
11.3.5.2. Market Revenue and Forecast, by Type of Therapy
11.3.5.3. Market Revenue and Forecast, by Diagnosis Method
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type of Cancer
11.3.6.2. Market Revenue and Forecast, by Type of Therapy
11.3.6.3. Market Revenue and Forecast, by Diagnosis Method
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type of Cancer
11.3.7.2. Market Revenue and Forecast, by Type of Therapy
11.3.7.3. Market Revenue and Forecast, by Diagnosis Method
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type of Cancer
11.4.2. Market Revenue and Forecast, by Type of Therapy
11.4.3. Market Revenue and Forecast, by Diagnosis Method
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type of Cancer
11.4.4.2. Market Revenue and Forecast, by Type of Therapy
11.4.4.3. Market Revenue and Forecast, by Diagnosis Method
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type of Cancer
11.4.5.2. Market Revenue and Forecast, by Type of Therapy
11.4.5.3. Market Revenue and Forecast, by Diagnosis Method
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type of Cancer
11.4.6.2. Market Revenue and Forecast, by Type of Therapy
11.4.6.3. Market Revenue and Forecast, by Diagnosis Method
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type of Cancer
11.4.7.2. Market Revenue and Forecast, by Type of Therapy
11.4.7.3. Market Revenue and Forecast, by Diagnosis Method
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type of Cancer
11.5.2. Market Revenue and Forecast, by Type of Therapy
11.5.3. Market Revenue and Forecast, by Diagnosis Method
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type of Cancer
11.5.4.2. Market Revenue and Forecast, by Type of Therapy
11.5.4.3. Market Revenue and Forecast, by Diagnosis Method
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type of Cancer
11.5.5.2. Market Revenue and Forecast, by Type of Therapy
11.5.5.3. Market Revenue and Forecast, by Diagnosis Method
12.1. Merck & Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AstraZeneca PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Roche Holding AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bristol Myers Squibb
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Johnson & Johnson
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AbbVie Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description